Recent reports from 46brooklyn, a nonprofit think tank, and IQVIA, a drug industry analytics firm, criticized the financial dynamics of 340B.

Two Reports Critique Financial Dynamics of 340B Program

March 19, 2024 William Newton, Associate Editor/Senior Writer Views

The 340B program may increase medication costs for self-insured employers, a recent study from a pharmaceutical industry outsourcing and analytics [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

Two Reports Critique Financial Dynamics of 340B Program

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

William Newton